Literature DB >> 29432733

DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1P29S mutation.

Takahiro Tomino1, Hirotada Tajiri1, Takaaki Tatsuguchi2, Takahiro Shirai3, Kounosuke Oisaki3, Shigeki Matsunaga4, Fumiyuki Sanematsu5, Daiji Sakata5, Tomoharu Yoshizumi6, Yoshihiko Maehara6, Motomu Kanai3, Jean-François Cote7, Yoshinori Fukui5, Takehito Uruno8.   

Abstract

Rac1 is a member of the Rho family of small GTPases that regulates cytoskeletal reorganization, membrane polarization, cell migration and proliferation. Recently, a self-activating mutation of Rac1, Rac1P29S, has been identified as a recurrent somatic mutation frequently found in sun-exposed melanomas, which possesses increased inherent GDP/GTP exchange activity and cell transforming ability. However, the role of cellular Rac1-interacting proteins in the transforming potential of Rac1P29S remains unclear. We found that the catalytic domain of DOCK1, a Rac-specific guanine nucleotide exchange factor (GEF) implicated in malignancy of a variety of cancers, can greatly accelerate the GDP/GTP exchange of Rac1P29S. Enforced expression of Rac1P29S induced matrix invasion and macropinocytosis in wild-type (WT) mouse embryonic fibroblasts (MEFs), but not in DOCK1-deficient MEFs. Consistently, a selective inhibitor of DOCK1 that blocks its GEF function suppressed the invasion and macropinocytosis in WT MEFs expressing Rac1P29S. Human melanoma IGR-1 and breast cancer MDA-MB-157 cells harbor Rac1P29S mutation and express DOCK1 endogenously. Genetic inactivation and pharmacological inhibition of DOCK1 suppressed their invasion and macropinocytosis. Taken together, these results indicate that DOCK1 is a critical regulator of the malignant phenotypes induced by Rac1P29S, and suggest that targeting DOCK1 might be an effective approach to treat cancers associated with Rac1P29S mutation.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Cytoskeleton; DOCK1; GEF; Invasion; Rac1

Mesh:

Substances:

Year:  2018        PMID: 29432733     DOI: 10.1016/j.bbrc.2018.02.073

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The pervasiveness of macropinocytosis in oncological malignancies.

Authors:  Cosimo Commisso
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 2.  The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic.

Authors:  Victoria Casado-Medrano; Martin J Baker; Cynthia Lopez-Haber; Mariana Cooke; Shaofei Wang; Maria J Caloca; Marcelo G Kazanietz
Journal:  Biochem Soc Trans       Date:  2018-07-31       Impact factor: 5.407

Review 3.  Rho GTPases in cancer: friend or foe?

Authors:  Julius H Svensmark; Cord Brakebusch
Journal:  Oncogene       Date:  2019-08-19       Impact factor: 9.867

4.  TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma.

Authors:  Wei Zhang; Xiaoxiao Zheng; Shangzhi Xie; Shufen Zhang; Jiayan Mao; Ying Cai; Xuemei Lu; Wei Chen; Haibin Ni; Liping Xie
Journal:  Mol Med Rep       Date:  2020-06-16       Impact factor: 2.952

5.  S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.

Authors:  Shuang Liu; Chunsheng Ni; Danfang Zhang; Huizhi Sun; Xueyi Dong; Na Che; Xiaohui Liang; Chen Chen; Fang Liu; Jingru Bai; Xian Lin; Xiulan Zhao; Baocun Sun
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

Review 6.  Targeting Rac and Cdc42 GEFs in Metastatic Cancer.

Authors:  Maria Del Mar Maldonado; Julia Isabel Medina; Luis Velazquez; Suranganie Dharmawardhane
Journal:  Front Cell Dev Biol       Date:  2020-04-08

Review 7.  RHO to the DOCK for GDP disembarking: Structural insights into the DOCK GTPase nucleotide exchange factors.

Authors:  Andrew P Thompson; Christina Bitsina; Janine L Gray; Frank von Delft; Paul E Brennan
Journal:  J Biol Chem       Date:  2021-03-05       Impact factor: 5.157

Review 8.  RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma.

Authors:  Paula Colón-Bolea; Rocío García-Gómez; Berta Casar
Journal:  Biomolecules       Date:  2021-10-20

Review 9.  Mutational drivers of cancer cell migration and invasion.

Authors:  Nikita M Novikov; Sofia Y Zolotaryova; Alexis M Gautreau; Evgeny V Denisov
Journal:  Br J Cancer       Date:  2020-11-18       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.